case_images: PMC7535118_01
case_images: General distribution of GNET patients. (A) Distribution of the patients' age follows a normal curve, with a range of 5 to 82 and a median of 36. The majority of patients were young adults aged 20 to 40 years. (B) Distribution of the follow-up time. The follow-up date was mainly within 48 months, with a median of 18 months and an average of 27.8 months.
case_images: OTT-13-9731-g0004.jpg
case_images: PMC7535118_01_OTT-13-9731-g0004.jpg
case_images: f0004
case_images: Patients were aged from 5 to 82 years old, with a median age of 36 years (Table 2, Figure 4A). The median follow-up time was 18 months, and the majority of follow-up times were within 48 months (89.2%) (Figure 4B).
case_images: The Kaplan-Meier survival curves of GNET patients. (A) The Kaplan-Meier's survival curve of all patients. The two-year disease-specific survival rate was approximately 71%. The median time to death and first metastasis was 61 and 12 months, respectively. The median follow-up time was 18 months. (B) The Kaplan-Meier's survival curve of TNM staging. People without lymph invaded or distant metastasis at first diagnosed also present of a better prognosis. (C) Staging of metastasis has a significant influence on disease-free survival time. People without metastases at diagnosis have an advantage to decrease postoperative metastases or recurrence. (D) K-M analysis shows a great difference in the overall survival time between populations of Grade 2 and Grade 3. It means that lower nuclear mitosis and lacking necrosis may link to a better prognosis. (E) Staging of independent lymphy metastasis (N) has a significant influence on overall survival time. People without lymphy metastasis when first diagnosed live a better predictive life. (F) The Kaplan-Meier's survival curve of adjuvant therapy. Aggressive chemoradiotherapy of GNET treatments are effective in patients' survival time.
case_images: OTT-13-9731-g0005.jpg
case_images: PMC7535118_01_OTT-13-9731-g0005.jpg
case_images: f0005
case_images: OS ranged from 0.69 to 161 months, with a median of 61 months (Figure 5A). Lymph node invasion or distant metastasis (M+N) had a significant influence on OS and DFS (Table 3) (Figure 5B and C). Independent lymph node metastasis (N), lower histological grades (G2), and aggressive chemoradiotherapy affected OS (P=0.027, P=0.039 and P=0.037) (Table 3) (Figure 5D-F).